Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells

Pancreas

Volumn 43, Issue 2, 2014, Pages 311-318

  Fujimura, Yoshinori ^a   Ikenaga, Naoki ^b   Ohuchida, Kenoki ^b   Setoyama, Daiki ^a   Irie, Miho ^c   Miura, Daisuke ^a   Wariishi, Hiroyuki ^a,c   Murata, Masaharu ^a,b   Mizumoto, Kazuhiro ^b,d   Hashizume, Makoto ^a,b   Tanaka, Masao ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b Graduate School of Medical Sciences   (United States)

^c Faculty of Agriculture   (United States)

^d KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

chemoresistance; gemcitabine; LC MS; metabolic profiling; pancreatic cancer

Indexed keywords

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DISCRIMINANT ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEAST-SQUARES ANALYSIS; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; PANCREATIC NEOPLASMS; PRINCIPAL COMPONENT ANALYSIS;

EID: 84894454543     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000092     Document Type: Article

References (53)

1. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378:607-620.
2. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
3. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27:2231-2237.
4. Makrilia N, Syrigos KN, Saif MW. Treatment for refractory pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP. 2011;12:110-113.
5. Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17(suppl 5):v7-v12.
6. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, et al. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2¶,2¶-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res. 2003;9:5000-5008.
7. Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer. 2007;97:145-151.
8. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2¶,2¶-difluorodeoxycytidine 5¶-triphosphate: a mechanism of self-potentiation. Cancer Res. 1992;52:533-539.
9. Eda H, Ura M, FO K, et al. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase. Cancer Res. 1998;58:1165-1169.
10. Mahon PC, Baril P, Bhakta V, et al. S100a4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res. 2007;67:6786-6795.
11. Ali S, Ahmad A, Banerjee S, et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue cdf. Cancer Res. 2010;70:3606-3617.
12. Ohuchida K, Mizumoto K, Kayashima T, et al. Microrna expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol. 2011;18:2381-2387.
13. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181-1189.
14. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer. 2004;4:551-561.
15. Soga T, Baran R, Suematsu M, et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem. 2006;281:16768-16776.
16. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008;134:714-717.
17. Denkert C, Budczies J, Kind T, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006;66:10795-10804.
18. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-914.
19. Merz AL, Serkova NJ. Use of nuclear magnetic resonance-based metabolomics in detecting drug resistance in cancer. Biomark Med. 2009;3:289-306.
20. Klawitter J, Kominsky DJ, Brown JL, et al. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol. 2009;158:588-600.
21. Fang F, He X, Deng H, et al. Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high-resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysis. Cancer Sci. 2007;98:1678-1682.
22. Kaplan O, Kushnir T, Askenazy N, et al. Role of nuclear magnetic resonance spectroscopy (MRS) in cancer diagnosis and treatment: 31P, 23Na, and 1h MRS studies of three models of pancreatic cancer. Cancer Res. 1997;57:1452-1459.
23. OuYang D, Xu J, Huang H, et al. Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis. Appl Biochem Biotechnol. 2011;165:148-154.
24. Bathe OF, Shaykhutdinov R, Kopciuk K, et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev. 2011;20:140-147.
25. Urayama S, Zou W, Brooks K, et al. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom. 2010;24:613-620.
26. Napoli C, Sperandio N, Lawlor RT, et al. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. J Proteome Res. 2012;11:1274-1283.
27. Sugimoto M, Wong DT, Hirayama A, et al. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6:78-95.
28. Miura D, Fujimura Y, Yamato M, et al. Ultrahighly sensitive in situ metabolomic imaging for visualizing spatiotemporal metabolic behaviors. Anal Chem. 2010;82:9789-9796.
29. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res. 2007;6:469-479.
30. Israel M, Schwartz L. The metabolic advantage of tumor cells. Mol Cancer. 2011;10:70.
31. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9:425-434.
32. Medina MA, Sanchez-Jimenez F, Marquez J, et al. Relevance of glutamine metabolism to tumor cell growth. Mol Cell Biochem. 1992;113:1-15.
33. Moreadith RW, Lehninger AL. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J Biol Chem. 1984;259:6215-6221.
34. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85-95.
35. Yao X, Zeng M, Wang H, et al. Metabolite detection of pancreatic carcinoma by in vivo proton MRspectroscopy at 3T: initial results. Radiol Med. 2012;117:780-788.
36. Sandgren EP, Quaife CJ, Paulovich AG, et al. Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc Natl Acad Sci U S A. 1991;88:93-97.
37. Hong SM, Park JY, Hruban RH, et al. Molecular signatures of pancreatic cancer. Arch Pathol Lab Med. 2011;135:716-727.
38. Shim H, Dolde C, Lewis BC, et al. c-myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A. 1997;94:6658-6663.
39. Yamamura S, Saini S, Majid S, et al. MicroRNA-34a modulates c-myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One. 2012;7:e29722.
40. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17:193-199.
41. Sotillo E, Laver T, Mellert H, et al. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene. 2011;30:2587-2594.
42. Dhayat S, Mardin WA, Mees ST, et al. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancerVa review. Int J Cancer. 2011;129:1031-1041.
43. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243-3251.
44. Kawauchi K, Araki K, Tobiume K, et al. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol. 2008;10:611-618.
45. Hirayama A, Kami K, Sugimoto M, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009;69:4918-4925.
46. Phang JM, Donald SP, Pandhare J, et al. The metabolism of proline, a stress substrate, modulates carcinogenic pathways. Amino Acids. 2008;35:681-690.
47. Liu Y, Borchert GL, Donald SP, et al. Proline oxidase functions as a mitochondrial tumor suppressor in human cancers. Cancer Res. 2009;69:6414-6422.
48. Maehara S, Tanaka S, Shimada M, et al. Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. Int J Cancer. 2004;112:184-189.
49. Wheatley DN. Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Semin Cancer Biol. 2005;15:247-253.
50. Crabtree MJ, Channon KM. Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. Nitric Oxide. 2011;25:81-88.
51. Fujita H, Ohuchida K, Mizumoto K, et al. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia. 2010;12:807-817.
52. Kolberg M, Strand KR, Graff P, et al. Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta. 2004;1699:1-34.
53. Hatse S, De Clercq E, Balzarini J. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Biochem Pharmacol. 1999;58:539-555.